Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.52 EUR
Change Today -0.029 / -0.52%
Volume 0.0
LMW On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:06 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (LMW) Snapshot

Open
€5.53
Previous Close
€5.55
Day High
€5.58
Day Low
€5.49
52 Week High
01/15/15 - €7.99
52 Week Low
05/22/14 - €2.56
Market Cap
346.3M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENOPORT INC (LMW)

xenoport inc (LMW) Related Businessweek News

No Related Businessweek News Found

xenoport inc (LMW) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase I clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is in Phase III clinical trials used for the treatment of spasticity in multiple sclerosis; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease has completed Phase II clinical trials. The company has a license agreement with Indivior PLC to develop and commercialize pharmaceutical products containing arbaclofen placarbil; license agreement with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan; and collaboration agreement with Glaxo Group Limited to develop and commercialize gabapentin enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

152 Employees
Last Reported Date: 02/27/15
Founded in 1999

xenoport inc (LMW) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $500.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $439.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $364.2K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $346.1K
Compensation as of Fiscal Year 2014.

xenoport inc (LMW) Key Developments

Xenoport, Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Xenoport, Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $7,067,000 against $3,375,000 a year ago. Loss from operations was $19,870,000 against $20,483,000 a year ago. Net loss was $20,409,000 or $0.33 per basic and diluted share against $20,548,000 or $0.36 per basic and diluted share a year ago.

Xenoport, Inc. to Report Q1, 2015 Results on May 06, 2015

Xenoport, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 06, 2015

Xenoport, Inc., Q1 2015 Earnings Call, May 06, 2015

Xenoport, Inc., Q1 2015 Earnings Call, May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LMW:GR €5.52 EUR -0.029

LMW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $8.10 USD -0.395
Emisphere Technologies Inc $0.46 USD -0.029
Flamel Technologies SA $17.74 USD -0.23
PlasmaTech Biopharmaceuticals Inc $8.77 USD -0.08
Skyepharma PLC 291.00 GBp -6.00
View Industry Companies
 

Industry Analysis

LMW

Industry Average

Valuation LMW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.7x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit www.xenoport.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.